Deming ct al. (1935a, b) and others Testosterone Van Cappellen (1933) and many others (see Vidgoff 1939) Inhibin Lower et al. (1935) Champy (1937) CEstrogen Wugmeister (1937) Moore & McClellan (1938) No treatment Clarke (1937) to explain some of the apparently contradictory results listed in Table 1 , which shows that good and bad results have been described following almost every type of endocrine treatment. Perhaps the most significant of these is in the series reported by Clarke (1937) (Watts 1968) . Lesser but annoying complications are common (Jeejeebhoy 1961 , Holtgrewe & Valk 1964 Based upon the somewhat shaky premise that benign prostatic hypertrophy is a result of changes in the hormonal milieu, androgens (Day 1939 , Kahle & Maltry 1940 , cestrogens (Roberts 1966 , Cook 1963 ) and progestogens (Geller et al. 1967 , Wolf & Madsen 1968 have been tried, but the results were confusing due to the methods by which the drugs were assessed.
Selection ofPatients
Our observations relate to a double-blind, controlled trial of spironolactone (Aldactone 50 mg b.d.). Patients given spironolactone had an overall improvement compared to placebo after three months of treatment, but this advantage was lost after six months (Castro et al. 1971) .
Patients with symptoms of bladder neck obstruction and benign enlargement of the prostate on digital rectal examination were studied. The following groups of patients were excluded from the trial: (1) (Castro et al. 1969) , particularly the postmicturition residual urine by planimetry (Griffiths & Castro 1970 (Table 1) . Maximal intravesical pressure increased significantly during the six months of placebo (P=0-02). This could reflect real deterioration or conscious straining. Other studies show that this measurement does not differentiate patients with benign prostatic hypertrophy from normals (Castro & Griffiths 1972) ; furthermore, it requires complicated apparatus and is not suitable for repeated measurements. In contrast, urinary flow rate can be easily measured; it was not affected by placebo and is the best objective measurement reflecting real change.
Conclusions
These studies show the importance of doubleblind, controlled trials in the clinical assessment of drugs thought to be useful in the treatment of benign prostatic hypertrophy. Many measurements used for assessing the patients changed when placebo was given and the most useful objective measurements were the maximal urinary flow rate and the residual urine measured by catheterization; these should be included in any trial of 'pills for the prostate'. Testosterone was first isolated in the mid 1930s, and since then has been regarded as the principal androgenic hormone responsible for developing and maintaining the activity of male accessory sex organs, such as the prostate. Recent studies in rats have qujestioned this concept because administration of tritium-labelled testosterone did not result in the accumulation of testosterone in the ventral prostatic tissue, but of a metabolite of this steroid, 5a-dihydrotestosterone (5aT) (Wilson 1970) . Furthermore, 'receptor' proteins which specifically bound 5aT were demonstrated in the cytoplasm of rat prostatic cells, and these were absent from non-target tissues that were examined. 5aT was probably transferred to the nuclei of prostatic cells by a process which involved these receptors.
These are important new observations, and some attempt must be made to relate them to the problems of human prostatic disease.
Studies on rat prostatic tissue have been carried out on normal animals, and it is difficult to compare these with studies of normal human tissue as this is only obtainable from autopsy specimens and prostates removed at total cystoprostatectomy. However, our studies have shown that the metabolism of testosterone in benign hyperplastic prostatic tissue in humans is similar to that in rats. Tritium-labelled testosterone (10 ,uCi) was administered intravenously to men undergoing open prostatectomy, and the principal radio-
